Camurus

aka Camurus AB, STO:CAMX

Camurus is a Swedish drug-delivery company whose FluidCrystal depot turns injections into long-acting formulations; CAM2029 is its monthly octreotide depot for acromegaly and neuroendocrine tumours.

Camurus develops long-acting medicines built on its FluidCrystal lipid-based depot technology, which forms a slow-release gel after subcutaneous injection. Its marketed products include Buvidal for opioid dependence. In oncology and endocrinology it is developing CAM2029 (octreotide subcutaneous depot, branded Oczyesa in some markets) for acromegaly, gastroenteropancreatic neuroendocrine tumours and polycystic liver disease, and in-licensed rights to a long-acting treprostinil.

Headquarters

Lund, SE

Scorecard

All companies

#310of 1181 companies, score 11

phase 3 +3
targets +2
modalities +2
registry trials +4

0 approved, 1 in phase 3, 0 earlier, 1 targets, 5 registry studies. Formula on the scorecards page.

Type

pharma · STO:CAMX

Stage

Public

Website

www.camurus.com/

Founded

1991

Products

1top

Phase 3Peptide somatostatin analogue (octreotide) in a long-acting subcutaneous depot

CAM2029 (octreotide subcutaneous depot)

CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations.

Connected